Manus Neurodynamica Limited, an Edinburgh, Scotland, UK-based medtech company, raised £1.2M in funding.
Investors included the North East Innovation Fund, supported by the European Regional Development Fund and managed by Northstar Ventures, profit with purpose investor SIS Ventures and Old College Capital, the University of Edinburgh’s venture fund.
The company intends to use the funds to launch its digital pen.
Led by CEO Rutger Zietsma, Manus Neurodynamica is advancing a digital pen which provides an early warning of Parkinson’s disease and other neurological conditions.
The NeuroMotor Pen employs sensors linked with analytical software which analyses the slightest limb and hand movements to help doctors assess whether a patient has early signs of Parkinson’s or other neurological conditions. As well as providing a non-invasive and objective aid to diagnosis, the CE-marked product also helps with the ongoing monitoring of those conditions.
With this latest funding secured, the company is rolling-out its NeuroMotor PenTM later this year, initially focusing on the UK and Benelux markets, while also progressing work to secure regulatory approval to start selling in US.